Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Randomized Controlled Trials to Define Viral Load Thresholds for Cytomegalovirus Pre-Emptive Therapy

29 Sept 2016

Abstract excerpt

BACKGROUND: To help decide when to start and when to stop pre-emptive therapy for cytomegalovirus infection, we conducted two open-label randomized controlled trials in renal, liver and bone marrow transplant recipients in a single centre where pre-emptive therapy is indicated if viraemia exceeds 3000 genomes/ml (2520 IU/ml) of whole blood. METHODS: Patients with two consecutive viraemia episodes each below 3000...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cytomegalovirus and herpesvirus research
Share to Hepatitis Viruses Studies and Epidemiology
Share to Viral-associated cancers and disorders

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 27684379
DOI: 10.1371/journal.pone.0163722

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Randomized Controlled Trials to Define Viral Load Thresholds for Cytomegalovirus Pre-Emptive TherapyPMID 27684379Read ↗

Cytomegalovirus Viral Load Threshold to Guide Preemptive Therapy in Hematopoietic Cell Transplant Recipients: Correlation With Cytomegalovirus DiseaseSemantic proximity Read ↗

Cytomegalovirus load at treatment initiation is predictive of time to resolution of viremia and duration of therapy in hematopoietic cell transplant recipientsSemantic proximity Read ↗

Surveillance of CMV Terminase Gene Mutations in Allogeneic Hematopoietic Stem Cell Transplant Recipients Receiving Letermovir ProphylaxisSemantic proximity Read ↗

Cytomegalovirus Antiviral Resistance Among Kidney Transplant Recipients in a Phase 3 Trial of Letermovir vs Valganciclovir Prophylaxis.Semantic proximity Read ↗

Letermovir Prophylaxis for Cytomegalovirus in Hematopoietic-Cell TransplantationSemantic proximity Read ↗

Algorithm based on CMV kinetics DNA viral load for preemptive therapy initiation after hematopoietic cell transplantationSemantic proximity Read ↗

Outcomes of patients with detectable CMV DNA at randomization in the phase III trial of letermovir for the prevention of CMV infection in allogeneic hematopoietic cell transplantationSemantic proximity Read ↗

Novel decay dynamics revealed for virus-mediated drug activation in cytomegalovirus infection.Semantic proximity Read ↗

Taming the Transplantation Troll by Targeting TerminaseSemantic proximity Read ↗

Early Kinetics of Plasma Cytomegalovirus DNA Load in Allogeneic Stem Cell Transplant Recipients in the Era of Highly Sensitive Real-Time PCR Assays: Does It Have Any Clinical Value?Semantic proximity Read ↗

Letermovir for primary and secondary cytomegalovirus prevention in allogeneic hematopoietic cell transplant recipients: Real‐world experienceSemantic proximity Read ↗

Time-Limited Therapy With Belatacept in Kidney Transplant RecipientsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.